<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04071366</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 39110-211</org_study_id>
    <nct_id>NCT04071366</nct_id>
  </id_info>
  <brief_title>A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy</brief_title>
  <official_title>A Phase 2, Single-Arm, Open-Label Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of oral administration of&#xD;
      itacitinib once daily for the prevention of cytokine release syndrome (CRS) in male or female&#xD;
      participants aged 12 years or older and who are planning to receive an approved immune&#xD;
      effector cell (IEC) therapy for hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2020</start_date>
  <completion_date type="Anticipated">July 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who develop ≥ Grade 2 CRS</measure>
    <time_frame>Day 14</time_frame>
    <description>Assessed using American Society for Blood and Marrow Transplantation (ASBMT) CRS Consensus Grading.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with immune effector cell-associated neurotoxicity syndrome (ICANS) after IEC therapy</measure>
    <time_frame>Day 28</time_frame>
    <description>Assessed using the ICANS Consensus Grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICANS regardless of CRS</measure>
    <time_frame>Day 28</time_frame>
    <description>Assessed using the ICANS Consensus Grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of all grades of CRS</measure>
    <time_frame>Day 28</time_frame>
    <description>Assessed using ASBMT CRS Consensus Grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with any grade of CRS after IEC therapy</measure>
    <time_frame>48 hours</time_frame>
    <description>Assessed using ASBMT CRS Consensus Grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥ Grade 2 CRS after first IEC therapy</measure>
    <time_frame>Day 28</time_frame>
    <description>Assessed using ASBMT CRS Consensus Grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events</measure>
    <time_frame>Day -3 through safety follow-up, up to approximately 60 days.</time_frame>
    <description>Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of itacitinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions for participants with CRS and/or ICANS</measure>
    <time_frame>Through end of study, up to 180 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay for participants with CRS and/or ICANS</measure>
    <time_frame>Through end of study, up to 180 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Cytokine Release Syndrome</condition>
  <arm_group>
    <arm_group_label>Itacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>Itacitinib 200 mg once daily for 30 days.</description>
    <arm_group_label>Itacitinib</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune effector cell therapy</intervention_name>
    <description>Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.</description>
    <arm_group_label>Itacitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible to receive an IEC therapy that is approved by the health authority in the&#xD;
             country where the study is being conducted, for hematologic indications.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0 to 1.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of active uncontrolled/untreated infection (viral, bacterial, fungal,&#xD;
             opportunistic) of any origin.&#xD;
&#xD;
          -  Evidence of active hepatitis B virus or hepatitis C virus infection.&#xD;
&#xD;
          -  Known human immunodeficiency virus.&#xD;
&#xD;
          -  Active acute or chronic graft-versus-host disease requiring systemic therapy.&#xD;
&#xD;
          -  Concurrent use of chronic systemic steroids or immunosuppressant medications.&#xD;
&#xD;
          -  Any unresolved toxicity ≥ Grade 2 (except stable Grade 2 peripheral neuropathy or&#xD;
             alopecia) from previous anticancer therapy.&#xD;
&#xD;
          -  Known history or prior diagnosis of immunologic or inflammatory/autoimmune disease&#xD;
             affecting the central nervous system (CNS) and unrelated to their disease under study&#xD;
             or previous treatment.&#xD;
&#xD;
          -  Clinically significant or uncontrolled cardiac disease.&#xD;
&#xD;
          -  Acute lymphoblastic leukemia participants with protocol-defined CNS status are&#xD;
             eligible only in the absence of neurologic symptoms suggestive of CNS leukemia.&#xD;
&#xD;
          -  Diffuse large B-cell lymphoma participants must have no signs or symptoms of CNS&#xD;
             disease or detectable evidence of CNS disease; participants who have been previously&#xD;
             treated for CNS disease but have no evidence of disease at screening are eligible.&#xD;
&#xD;
          -  Laboratory values at screening outside the protocol-defined ranges.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Langmuir, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytokine release syndrome</keyword>
  <keyword>immune effector cell-associated neurotoxicity syndrome</keyword>
  <keyword>Janus kinase inhibitor</keyword>
  <keyword>immune effector cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cytokine Release Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

